Holen Sie sich die Stockscreener-App
1.18
6.35%
-0.08
Handel nachbörslich:
1.21
0.03
+2.54%
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
Cardiff Oncology (CRDF) director receives 40,565 stock options grant - Stock Titan
Cardiff Oncology (CRDF) director receives grant of 40,565 stock options at $1.59 - Stock Titan
Cardiff Oncology Shareholders Approve Directors and Equity Plan - TipRanks
Cardiff Oncology (CRDF) shareholders back board, auditor and equity plan - Stock Titan
Cardiff Oncology (CRDF) Holds Steady at $1.50 as Key Levels Define Trading RangeProtective Put - newsline.com
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal CancerSlideshow (NASDAQ:CRDF) 2026-06-07 - Seeking Alpha
Lucid Capital Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
CRDF Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Upda - GuruFocus
CRDF Downgraded by Craig-Hallum -- Price Target Lowered to $2.00 - GuruFocus
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Update - GuruFocus
Cardiff Oncology unveils promising Phase 2 onvansertib data - TipRanks
Onvansertib Phase 2 results move Cardiff Oncology (NASDAQ: CRDF) toward Phase 3 - Stock Titan
Cardiff Oncology Inc Call on Updated Phase 2 CRDF-004 Transcript - GuruFocus
Cardiff Oncology (CRDF) Reports Promising Phase 2 Results for On - GuruFocus
Cardiff Oncology reports positive phase 2 trial results for onvansertib By Investing.com - Investing.com Australia
Cardiff Oncology reports positive phase 2 trial results for onvansertib - Investing.com
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in RAS-Mutated Metastatic Colorectal Cancer, Plans Registrational Study - Quiver Quantitative
Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting - TradingView
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting - The Manila Times
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Clinical-stage biotech CEO in Jefferies health conference fireside chat - Stock Titan
Cardiff Oncology Shares Fall After HC Wainwright, TD Cowen Downgrades - marketscreener.com
CRDF Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
CRDF Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Cardiff Oncology (CRDF) Files Lawsuit Against Nerviano Medical S - GuruFocus
TD Cowen Downgrades Cardiff Oncology to Hold From Buy - Moomoo
H.C. Wainwright cuts Cardiff Oncology stock rating on license termination By Investing.com - Investing.com Canada
TD Cowen downgrades Cardiff Oncology stock rating on license dispute By Investing.com - Investing.com Canada
This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Sahm
Cardiff Oncology, Inc. 8-K Filing Details for May 27, 2026: Company Information, NASDAQ Listing, and Key Disclosures - Minichart
Cardiff OncologyNms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026 - TradingView
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Cardiff Oncology 1Q Loss/Shr 18c >CRDF - Moomoo
Cardiff Oncology (CRDF) Hovering Near Support as Modest Decline ExtendsRounding Top - newsline.com
CRDF: First Quarter 2026 Results - Zacks Small Cap Research
Cardiff Oncology to host webcast on cancer trial data By Investing.com - Investing.com South Africa
Cardiff Oncology to host webcast on cancer trial data - Investing.com UK
New colorectal cancer trial data heads to ASCO, investor webcast June 3 - Stock Titan
Cardiff Oncology Announces Webcast to Discuss Updated Phase - GlobeNewswire
Cardiff Oncology sues Nerviano as analyst backs Onvansertib defense - MSN
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Benzinga
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights - TipRanks
Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the in - Bitget
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):